Loading
NKT5097 is an experimental protein degrader from NiKang Therapeutics, in phase 1 trials for HR-positive breast cancer and CCNE1-amplified solid tumours.
NKT5097 is a small molecule degrader, oral from NiKang Therapeutics. A dual degrader of CDK2 and CDK4, cell-cycle enzymes. The phase 1 study NCT07029399 tests it alone and with fulvestrant or letrozole. Whether it works in people has not been established.
A dual degrader of CDK2 and CDK4, cell-cycle enzymes. Connects to CDK2.
1.NKT5097 binds CDK2 with one end and an E3 ubiquitin ligase with the other.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"NKT5097" OR ABSTRACT:"NKT5097") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NKT5097, not a curated reading list.
Shares CDK2, NiKang Therapeutics and the tag pipeline.
Shares CDK2 and the tag pipeline.
Shares CDK2 and the tag pipeline.
Shares CDK2 and the tag pipeline.
Shares CDK2 and the tag pipeline.
Shares NiKang Therapeutics and the tag pipeline.
Shares NiKang Therapeutics and the tag pipeline.
Shares NiKang Therapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/